Predictors of Response to Acute Treatment of Chronic and Double Depression With Sertraline or Imipramine
Robert M. A. Hirschfeld(The University of Texas Medical Branch at Galveston), Robert Miceli(Pfizer (United States)), Pedro L. Delgado(Harvard University), Richard A. Friedman(National Heart Lung and Blood Institute), Michael E. Thase(Veterans Health Administration), Margaret A. Connolly(Shell (United States)), James M. Russell(The University of Texas Medical Branch at Galveston), Ivan W. Miller(Miriam Hospital), Robert H. Howland(University of Pittsburgh), Jan Fawcett, Wilma Harrison(Pfizer (United States))
Cited by 124
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication
|Archives of General Psychiatry|2007|2.4k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
|Controlled Clinical Trials|2004|1.1k
Frontiers of cognitive therapy
|General Hospital Psychiatry|1997|1.1k